News

Article

In the Lab eNewsletter

Pharmaceutical Technology's In the Lab eNewsletter, December 2022
Volume17
Issue 12

FDA Publishes Draft Guidance Concerning Sameness in ANDAs

The latest guidance from FDA discusses recommendations on demonstrating sameness between the active ingredient in a proposed generic drug product and its reference listed drug.

FDA published a draft guidance concerning sameness evaluations in abbreviated new drug applications (ANDAs) on Nov. 8, 2022. The guidance discusses recommendations on demonstrating sameness between the active ingredient in a proposed generic drug product and its reference listed drug.

In addition to general recommendations on demonstrating sameness, the guidance provides additional considerations for products like synthetic peptides and complex mixtures. The guidance also provides non-binding examples of active ingredient characterization in the drug product.

The draft guidance can be viewed in full here. FDA is soliciting comments on the guidance through Jan. 8, 2022.

Source: FDA

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Related Content